Broken String Biosciences is pioneering advancements in gene editing therapies with its innovative technology platform, INDUCE-seq®. This cutting-edge DNA break-mapping technology is designed to enhance the safety and efficacy of cell and gene therapies by accurately characterizing genome breaks. By focusing on the specificity of CRISPR and other genome editing techniques, INDUCE-seq® addresses the critical challenge of off-target effects, which can pose significant risks in therapeutic applications. The platform has demonstrated its capability to identify structural DNA changes that influence CRISPR targeting specificity, thereby providing essential insights for the development of safer gene editing strategies.

The company, founded as a spinout from Cardiff University, aims to create transformative therapeutics that are safer by design. With a strong emphasis on genomic stability, Broken String Biosciences is actively collaborating with academic and industrial partners to further its research and development efforts. The integration of machine learning and automation into their technology platform is also part of their strategy to enhance the assessment of genome editing activities. As they continue to expand their capabilities, Broken String is positioned to play a significant role in the evolution of gene editing therapies, ultimately improving patient outcomes in various genetic disorders.

United Kingdom

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs

Broken String Biosciences

Company Details